Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company based in Bethesda, MD, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' chairman and chief executive officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding chief executive officer and advisor, international business development.

In January 2006, Sucampo received marketing approval from the U.S. Food and Drug Administration for its first product, AMITIZAŽ (lubiprostone) (24 mcg), for the treatment of Chronic Idiopathic Constipation in adults. In April 2008, AMITIZA (8 mcg) was approved by the FDA for a second indication, Irritable Bowel Syndrome with Constipation (IBS-C) in women 18 years and older.

 

Nov 19, 2009
Sucampo Receives Marketing Authorization for Amitiza(R) in Switzerland for Treatment of Chronic Idiopathic Constipation

Nov 6, 2009
Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of Presentation at Credit Suisse Conference

Nov 5, 2009
Sucampo Pharmaceuticals Reports Financial Results for the Third Quarter of 2009